244 related articles for article (PubMed ID: 28560739)
1. Predictive value of different prostate-specific antigen-based markers in men with baseline total prostate-specific antigen <2.0 ng/mL.
Fujizuka Y; Ito K; Oki R; Suzuki R; Sekine Y; Koike H; Matsui H; Shibata Y; Suzuki K
Int J Urol; 2017 Aug; 24(8):602-609. PubMed ID: 28560739
[TBL] [Abstract][Full Text] [Related]
2. Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer.
Basourakos SP; Davis JW; Chapin BF; Ward JF; Pettaway CA; Pisters LL; Navai N; Achim MF; Wang X; Chen HC; Choi S; Kuban D; Troncoso P; Hanash S; Thompson TC; Kim J
BJU Int; 2018 Jan; 121(1):69-76. PubMed ID: 28710901
[TBL] [Abstract][Full Text] [Related]
3. Primary Gleason pattern upgrading in contemporary patients with D'Amico low-risk prostate cancer: implications for future biomarkers and imaging modalities.
Leyh-Bannurah SR; Abou-Haidar H; Dell'Oglio P; Schiffmann J; Tian Z; Heinzer H; Huland H; Graefen M; Budäus L; Karakiewicz PI
BJU Int; 2017 May; 119(5):692-699. PubMed ID: 27367469
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of an Aggressive Prostate Biopsy Strategy in Men Younger than 50 Years.
Goldberg H; Klaassen Z; Chandrasekar T; Wallis CJD; Toi A; Sayyid R; Bhindi B; Nesbitt M; Evans A; van der Kwast T; Sweet J; Perlis N; Hamilton RJ; Kulkarni GS; Finelli A; Zlotta A; Fleshner N
J Urol; 2018 Nov; 200(5):1056-1061. PubMed ID: 29758220
[TBL] [Abstract][Full Text] [Related]
5. Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance.
Perlis N; Sayyid R; Evans A; Van Der Kwast T; Toi A; Finelli A; Kulkarni G; Hamilton R; Zlotta AR; Trachtenberg J; Ghai S; Fleshner NE
J Urol; 2017 Jan; 197(1):75-83. PubMed ID: 27457260
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic Impacts of Clinical Laboratory Based p2PSA Indexes on any Grade, Gleason Grade Group 2 or Greater, or 3 or Greater Prostate Cancer and Prostate Specific Antigen below 10 ng/ml.
Ito K; Yokomizo A; Tokunaga S; Arai G; Sugimoto M; Akakura K; Hasumi H; Sakai H; Ouraji A; Oki R; Kashiwagi E; Kobori Y; Hirama H; Kitoh H; Uemura H; Hakariya T; Suzuki K;
J Urol; 2020 Jan; 203(1):83-91. PubMed ID: 31430244
[TBL] [Abstract][Full Text] [Related]
7. Cumulative risk of developing prostate cancer in men with low (≤ 2.0 ng/mL) prostate-specific antigen levels: a population-based screening cohort study in Japan.
Sawada K; Kitagawa Y; Ito K; Takeda Y; Mizokami A; Namiki M
Int J Urol; 2014 Jun; 21(6):560-5. PubMed ID: 24372775
[TBL] [Abstract][Full Text] [Related]
8. Impact of PSA levels on second-round screening for the development of prostate cancer in men with low baseline PSA levels (≤2.0 mg/ml).
Kitagawa Y; Sawada K; Urata S; Izumi K; Ueno S; Kadono Y; Konaka H; Mizokami A; Namiki M
Anticancer Res; 2014 Nov; 34(11):6739-46. PubMed ID: 25368284
[TBL] [Abstract][Full Text] [Related]
9. Metastatic Prostate Cancer in Men Initially Treated with Active Surveillance.
Yamamoto T; Musunuru HB; Vesprini D; Zhang L; Ghanem G; Loblaw A; Klotz L
J Urol; 2016 May; 195(5):1409-1414. PubMed ID: 26707510
[TBL] [Abstract][Full Text] [Related]
10. Predictive role of free prostate-specific antigen in a prospective active surveillance program (PRIAS).
Vasarainen H; Salman J; Salminen H; Valdagni R; Pickles T; Bangma C; Roobol MJ; Rannikko A
World J Urol; 2015 Nov; 33(11):1735-40. PubMed ID: 25822705
[TBL] [Abstract][Full Text] [Related]
11. Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer.
Ellis WJ; Etzioni R; Vessella RL; Hu C; Goodman GE
J Urol; 2001 Jul; 166(1):93-8; discussion 98-9. PubMed ID: 11435831
[TBL] [Abstract][Full Text] [Related]
12. Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer.
Adamy A; Yee DS; Matsushita K; Maschino A; Cronin A; Vickers A; Guillonneau B; Scardino PT; Eastham JA
J Urol; 2011 Feb; 185(2):477-82. PubMed ID: 21167529
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Serum microRNA Biomarkers to Predict Reclassification of Prostate Cancer in Patients on Active Surveillance.
Liu RSC; Olkhov-Mitsel E; Jeyapala R; Zhao F; Commisso K; Klotz L; Loblaw A; Liu SK; Vesprini D; Fleshner NE; Bapat B
J Urol; 2018 Jun; 199(6):1475-1481. PubMed ID: 29246734
[TBL] [Abstract][Full Text] [Related]
14. [-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study.
Sokoll LJ; Wang Y; Feng Z; Kagan J; Partin AW; Sanda MG; Thompson IM; Chan DW
J Urol; 2008 Aug; 180(2):539-43; discussion 543. PubMed ID: 18550118
[TBL] [Abstract][Full Text] [Related]
15. Pathological Outcome following Radical Prostatectomy in Men with Prostate Specific Antigen Greater than 10 ng/ml and Histologically Favorable Risk Prostate Cancer.
Yu J; Kwon YS; Kim S; Han CS; Farber N; Kim J; Byun SS; Kim WJ; Jeon SS; Kim IY
J Urol; 2016 May; 195(5):1464-1470. PubMed ID: 26608903
[TBL] [Abstract][Full Text] [Related]
16. Individualized estimates of overdiagnosis in screen-detected prostate cancer.
Gulati R; Inoue LY; Gore JL; Katcher J; Etzioni R
J Natl Cancer Inst; 2014 Feb; 106(2):djt367. PubMed ID: 24399850
[TBL] [Abstract][Full Text] [Related]
17. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.
Hattangadi JA; Chen MH; D'Amico AV
BJU Int; 2012 Dec; 110(11):1636-41. PubMed ID: 22757982
[TBL] [Abstract][Full Text] [Related]
18. Risk of prostate cancer for young men with a prostate specific antigen less than their age specific median.
Loeb S; Nadler RB; Roehl KA; Antenor JA; Catalona WJ
J Urol; 2007 May; 177(5):1745-8. PubMed ID: 17437803
[TBL] [Abstract][Full Text] [Related]
19. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
Roobol MJ; Kranse R; de Koning HJ; Schröder FH
Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]